Antibody Drug Conjugates (ADC) Industry Report 2024 –

Dublin, November 5, 2024 (GLOBE NEWSWIRE) — The “Antibody Drug Conjugates (ADC) – Global Strategic Business Report” has been updated ResearchAndMarkets.com Offer.

The global antibody drug conjugates (ADC) market was valued at $9.4 billion in 2023 and is expected to reach $23.2 billion by 2030, growing at a CAGR of 13.8% from 2023 by 2030.

Antibody-drug conjugates (ADCs) are a cutting-edge class of biopharmaceuticals designed to target and treat cancer. ADCs combine the targeting ability of monoclonal antibodies with potent cytotoxic drugs, allowing them to deliver chemotherapy drugs directly to cancer cells while minimizing damage to healthy tissue. This targeted approach has made ADCs an increasingly attractive option in oncology, particularly in cancers that have proven resistant to conventional treatments. By using monoclonal antibodies that bind to specific proteins on the surface of cancer cells, ADCs can deliver toxic payloads more efficiently, improving therapeutic outcomes while reducing systemic side effects. ADCs are used in the treatment of various types of cancer, including breast cancer, lymphoma, and solid tumors.

How is the ADC market segmented and what are the main applications?

Technologically, the market is segmented into the types of linkers and payloads used, which are crucial components in ensuring the stability and effectiveness of the drug. In terms of application, breast cancer currently dominates the ADC market, with treatments such as Kadcyla and Enhertu having a high success rate. Other target indications include hematological malignancies and solid tumors. Ongoing clinical trials aim to expand the use of ADCs to additional types of cancer.

End users primarily include hospitals, oncology clinics and cancer research institutes where ADCs are administered as part of comprehensive cancer treatment plans. North America is leading the market due to its advanced healthcare infrastructure and heavy investment in oncology research, while Europe and Asia Pacific are emerging as key regions due to increasing healthcare spending and rising cancer prevalence.

How are technological innovations affecting the ADC market?

Technological advances play a critical role in the growth and effectiveness of ADCs. Innovations in linker chemistry have improved the stability and precision of ADCs, enabling better drug delivery at the cancer site and reducing off-target toxicity. Advances in cytotoxic payloads are also increasing the potency of ADCs, making them more effective against drug-resistant cancer cells.

Additionally, ongoing research to identify new cancer biomarkers expands the potential applications of ADCs beyond current use cases and enables the development of next-generation ADCs that target previously untreatable cancers. Regulatory agencies such as the FDA are also accelerating the approval of new ADC therapies, recognizing their potential to transform cancer treatment.

What factors are driving the growth of the antibody drug conjugates market?

The growth of the antibody drug conjugates (ADC) market is driven by several factors, including the increasing prevalence of cancer and the demand for more targeted, effective treatments. Advances in linker technologies and payload delivery systems have improved the efficacy and safety profile of ADCs and contributed to their increasing acceptance in oncology. Additionally, the rise of personalized medicine, where treatments are tailored to individual patients based on genetic and molecular markers, is driving the development of ADCs. The clinical success and approval of leading ADC products have led to further investments in research and development and expanded the pipeline for future ADC therapies. Additionally, growing awareness and demand for therapies with fewer side effects compared to traditional chemotherapy continue to drive market growth.

Key Takeaways:

• Market Growth: Understand the significant growth trajectory of the breast cancer end-use segment, which is expected to reach $11 billion by 2030, with a compound annual growth rate of 14.5%. The blood cancer end-use segment is also expected to grow at a CAGR of 13.4% during the analysis period.
• Regional Analysis: Gain insight into the US market, valued at $2.6 billion in 2023, and China, which is expected to grow at an impressive 18.5% annually to $5.2 billion by 2030. Dollar is forecast. Discover growth trends in other key regions including Japan and Canada, Germany and Asia Pacific.

Key questions answered:

• How is the global antibody drug conjugates (ADC) market expected to develop by 2030?
• What are the key drivers and restraints affecting the market?
• Which market segments will grow the most during the forecast period?
• How will the market shares of different regions and segments change by 2030?
• Who are the leading players in the market and what are their prospects?

Reporting features:

• Comprehensive market data: Independent analysis of annual sales and market forecasts in millions of US dollars from 2023 to 2030.
• Detailed Regional Analysis: Detailed insights into key markets including the US, China, Japan, Canada, Europe, Asia Pacific, Latin America, the Middle East and Africa.
• Company Profiles: Covering key players in the antibody drug conjugates (ADC) market such as ADC Therapeutics SA, Astellas Pharma, Inc., AstraZeneca Plc, Daiichi Sankyo Co., Ltd., Enzo Biochem, Inc. and more.
• Free Updates: Receive one year of free report updates to keep you up to date on the latest market developments.

The 52 companies featured in this Antibody Drug Conjugates (ADC) market report include:

• ADC Therapeutics
• Astellas Pharma
• AstraZeneca
• Daiichi Sankyo Co.
• Enzo Biochem
• F. Hoffmann-La Roche
• Gilead Sciences
• GSK
• ImmunoGen
• MabPlex International

Key attributes:

Main topics covered:

MARKET OVERVIEW

• World market trends
• Antibody-Drug Conjugates (ADC) – Percentage Market Share of Key Global Competitors in 2024 (E)
• Competitive market presence – strong/active/niche/trivial for players worldwide in 2024 (E)

Focus on selected players

• ADC Therapeutics
• Astellas Pharma
• AstraZeneca
• Daiichi Sankyo Co.
• Enzo Biochem
• F. Hoffmann-La Roche
• Gilead Sciences
• GSK
• ImmunoGen
• MabPlex International

Market trends and drivers

• Rising cancer prevalence is increasing the demand for targeted therapy solutions
• Technological advancements in biopharmaceuticals are driving the growth of the ADC market
• Precision Medicine's expansion strengthens the business model for antibody-drug conjugates
• Increasing focus on immuno-oncology drives innovation in ADC development
• Advances in targeted drug delivery systems are driving the growth of ADC therapies
• The increasing use of ADCs in hematological malignancies is increasing the market demand
• Increasing interest in combination therapies strengthens the acceptance of ADCs in cancer treatment
• Increasing focus on personalized medicine expands the addressable market for ADC-based therapies
• Growing awareness of precision therapeutics is driving demand for targeted cancer therapies
• Advances in payload and linker technologies create opportunities for innovative ADC products
• Increasing prevalence of chronic diseases beyond cancer expands the applications of ADCs

For more information about this report, see

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source of international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

• Antibody Drug Conjugates (ADC) Market.